Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Status:
Recruiting
Trial end date:
2022-12-17
Target enrollment:
Participant gender:
Summary
Investigators are testing new experimental drug combinations such as the combination of
vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may
be effective against tumors that have come back or that have not responded to standard
therapy.
The goals of this study are:
- To find the highest safe dose of vorinostat that can be given together with vincristine,
irinotecan, and temozolomide without causing severe side effects;
- To learn what kind of side effects this four drug combination can cause;
- To learn about the effects of vorinostat and the combination of vorinostat, vincristine,
irinotecan, and temozolomide on specific molecules in tumor cells;
- To determine whether the combination of vorinosat, vincristine, irinotecan, and
temozolomide is a beneficial treatment.